HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Contrariwise, although the variant in HSD17B13 was linked with decreased levels of the spliced variant, it has been associated with protection against alcoholic and non-alcoholic fatty liver disease and against the progression towards fibrosis and HCC [18].